STOCK TITAN
  1. Home
  2. Sec-filings
  3. FENC
  4. [Form 4] FENNEC PHARMACEUTICALS INC. Insider Trading Activity

Fennec Pharmaceuticals (NASDAQ: FENC) CEO reports 1,159-share award release

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Executive Officer Jeffrey S. Hackman reported a compensation-related share acquisition. On June 30, 2026, he received 1,159 Common Shares at no purchase price, reflecting shares released from restriction from an award granted on March 28, 2025. Following this release, he directly owns 63,984 Common Shares. This filing records a routine equity award release rather than an open-market trade.

Positive

  • None.

Negative

  • None.
Insider Hackman Jeffrey S.
Role Chief Executive Officer
Type Security Shares Price Value
Grant/Award Common Shares 1,159 $0.00 --
Holdings After Transaction: Common Shares — 63,984 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Shares acquired 1,159 shares Grant, award, or other acquisition on June 30, 2026
Transaction price $0.0000 per share Reported for 1,159 Common Shares acquired
Shares after transaction 63,984 shares Total Common Shares directly owned following June 30, 2026 transaction
Award grant date March 28, 2025 Original award from which 1,159 shares were released from restriction
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
Common Shares financial
"security_title: Common Shares"
Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.
released from restriction financial
"Represents shares released from restriction from shares awarded 3/28/2025."
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hackman Jeffrey S.
(Last)(First)(Middle)
68 TW ALEXANDER DRIVE
PO BOX 13628
(Street)
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
Chief Executive Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares(1)06/30/2026A1,159A$063,984D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares released from restriction from shares awarded 3/28/2025.
/s/ Jeffrey Hackman07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did FENC CEO Jeffrey Hackman report on this Form 4?

Jeffrey Hackman reported receiving 1,159 FENC Common Shares as a grant-related acquisition. The shares were released from restriction from an award dated March 28, 2025, and were not purchased on the open market.

Was the FENC CEO’s June 30, 2026 transaction an open-market buy or sell?

The June 30, 2026 transaction was not an open-market trade. It reflects a grant or award acquisition, with restricted shares becoming unrestricted, and a reported price of $0.0000 per share for the 1,159 shares.

How many FENC shares does CEO Jeffrey Hackman hold after this reported transaction?

After the June 30, 2026 release of restrictions, Jeffrey Hackman holds 63,984 FENC Common Shares directly. This total includes the 1,159 shares that became unrestricted from the prior equity award granted on March 28, 2025.

What is the significance of the footnote in Jeffrey Hackman’s FENC Form 4 filing?

The footnote explains the 1,159 shares represent a release from restriction on shares awarded March 28, 2025. This clarifies the transaction is part of an existing equity award vesting process rather than a new purchase or sale decision in the market.

How is the FENC CEO’s Form 4 transaction coded and what does it mean?

The transaction is coded “A” for “Grant, award, or other acquisition,” indicating shares received through compensation. It aligns with the footnote describing restricted shares becoming unrestricted, not an open-market buy or sell of FENNEC PHARMACEUTICALS stock.